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ABSTRACT 
 
Ubiquitin has previously been identified as another natural agonist of CXC 
chemokine receptor 4 (CXCR4). In addition, recent evidence suggests that ubiquitin may 
activate CXCR4 through a binding site on the receptor, which is distinct from the binding site 
for the cognate ligand stromal cell-derived factor (SDF)-1!. The cellular consequences of 
ubiquitin induced CXCR4 activation, however, are still poorly defined and a side-by-side 
comparison of CXCR4 mediated functions after activation with SDF-1! and ubiquitin is 
lacking. Such information will be instrumental to better understand the physiological 
function of CXCR4 and to further define its role as a therapeutic target in various disease 
processes. Accordingly, the aim of this study was to determine and compare CXCR4 
mediated effects on important signal transduction pathways and chemotaxis, a key function 
of CXCR4, upon receptor activation with ubiquitin and SDF-1!. Utilizing a MAPK array in 
combination with Western blot experiments, it is shown that activation of CXCR4 with 
ubiquitin and SDF-1! in THP-1 cells leads to increased phosphorylation of extracellular 
signal-related kinase (ERK) 1/2, ribosomal S6 kinase (RSK) 1, and protein kinase B (Akt). 
Analyses of the time progression of the MAPK phosphorylation revealed that both ligands 
induced a comparable degree of MAPK phosphorylation, which occurred transiently after 
activation of CXCR4 with ubiquitin and was sustained for at least 30 minutes with SDF-1!. 
To assess CXCR4 mediated chemotaxis, a filter migration assay was established and 
optimized. It is shown that THP-1 cells and human peripheral blood mononuclear cells 
 
 
ix 
migrate dose dependently towards ubiquitin and SDF-1!. Under optimized conditions, 
ubiquitin was 4-5 times less efficacious than SDF-1! in promoting chemotaxis, but of similar 
potency. Pharmacological inhibition of signal transduction molecules that are known to be 
involved in the regulation of CXCR4 mediated chemotaxis resulted in similar effects on 
ubiquitin and SDF-1! induced chemotaxis in THP1 cells and PBMCs. This suggests that 
both ligands rely on a similar pattern of intracellular signaling to induce chemotaxis. In 
conclusion, activation of CXCR4 with ubiquitin and SDF-1! results in similar intracellular 
signaling events and functional consequences. With activation of CXCR4 by ubiquitin, 
however, serine/threonine protein kinase phosphorylations occurred more transiently, which 
could account for its weaker chemotactic activity, as compared with SDF-1!. Thus, ubiquitin 
appears to be a weaker CXCR4 agonist than SDF-1!, which may correspond to differential 
CXCR4 signaling mediated via distinct ligand binding sites on the receptor.
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CHAPTER ONE 
INTRODUCTION 
G-protein coupled receptors  
G-protein coupled receptors (GPCRs) are a large superfamily of transmembrane 
spanning receptor proteins found in the human genome and are present in all eukaryotes (1-
3). The superfamily is further divided into three main sub-families: the most prominent being 
rhodopsin related (type A), receptors related to secretin/calcitonin (type B) and receptors 
related to the metabotropic receptors (type C) (4). All GPCRs have an extracellular N-
terminal segment, a seven transmembrane spanning region, which form the transmembrane 
core, three extra cellular loops, three cytoplasmic loops, and an intracellular C-terminal 
segment. Ligand binding to the extracellular region causes a receptor conformational change 
(5,6) and GPCRs fluctuate between an active and inactive conformation (11). In the active 
state, they utilize several molecular mechanisms to induce a cellular response through two 
distinct signaling pathways (Figure 1-1): G-protein mediated signaling, the predominant 
signaling pathway, and G-protein independent signaling (7-9).  
In the G-protein mediated signaling pathway, a heterotrimeric G-protein complex 
comprised of !"# subunits are in an inactive state at the receptor and the localization is a 
result of the G! subunit being bound to GDP (46-48). The binding of an agonist induces an 
activating conformational receptor shift (49, 50). This shift enables GPCRs to act as a 
guanine nucleotide exchange factor, promoting the heterotrimeric G-protein activation 
resulting in GDP to GTP exchange at the G! subunit (49,50) Subsequently, there is a 
conformational change in the heterotrimeric G-protein complex resulting in G! and G"#
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disassociation and activation of various second messengers leading to a functional cellular 
response (49, 50).  
The G-protein independent signaling pathway is well established through "-arrestin 
mediated signaling (8, 45, 60-63). This pathway requires receptor phosphorylation, 
classically by G-protein-coupled receptor kinases (GRKs), but also by cAMP dependent 
kinase A (PKA) or PKC on the third intracellular loop of the GPCR enabling "-arrestin to 
target the receptor (8, 60). Upon receptor phosphorylation, arrestin-2 and/or arrestin-3 are 
then able to bind; preventing further G-protein mediated signaling (8,45,60-63). This 
pathway plays a role in regulating G! interactions and is predominantly responsible for 
receptor desensitization, internalization, and degradation (29).  
 
Figure 1-1: GPCRs can signal through two distinct signaling pathways: 1. G-protein 
(left), GPCR signals through G-protein activation. 2. "-arrestin (right), GPCR signals 
through "-arrestin. 
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Functional selectivity (biased agonism), a phenomenon that occurs when a ligand 
preferentially stabilizes an active conformation promoting only a subset of signaling effects 
(11-16), has gained particular attention with respect to GPCR mediated signaling. GPCRs are 
capable of adopting different active conformational states and this could lead to preferential 
(biased) G-protein dependent or independent signaling (10). While most GPCR-mediated 
biased signaling has been observed using synthetic agonists (14), C-C motif chemokine 19 
and 21 (CCL19/21), natural agonists for GPCR C-C chemokine receptor 7 (CCR7), have 
been shown to produce G-protein signaling with equal potency. CCL19 alone causes receptor 
agonist-dependent phosphorylation and "-arrestin recruitment to terminate G-protein 
signaling (14). There is therapeutic promise to understanding GPCR mediated biased 
signaling because it broadens the scope of drug discovery tailored to receptor ligand 
specificity. 
 
Chemokine receptors 
Chemokine receptors are a member of the rhodopsin related (type A, subfamily A1 
and A2) GPCR superfamily and are involved in immune system functions (17-19). The 
interaction of chemokine receptors with chemokines regulates cell migration for multiple cell 
types including leukocytes (100, 101). The receptors are classified on the basis of the ligand 
specificity for a particular chemokine class. The four main classes of chemokines are CC, 
CXC, CX3C and C, according to the number and spacing of conserved cysteines in the 
amino acid sequence (20, 21). Structure-function studies have shown that the chemokine-
receptor interaction follows a 2-site binding model (Figure 1-2). In this model, the 
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extracellular N-terminal domain of the chemokine receptor (site I) initially interacts with a 
ligand for binding. The ligand then interacts with the chemokine receptor at a different 
receptor extracellular site (site II) to induce an activation signal (24, 43). It is known that 
there are 19 human chemokine receptors and over 50 distinct chemokines. As a result, 
chemokine receptors, like CCR7, are promiscuous in that they can bind more than one 
chemokine (14, 22, 23).  
 
 
Figure 1-2:Two site binding model of the chemokine – receptor interaction. Depicted is a 
model of the chemokine-chemokine receptor interaction. Chemokines binds to a site on the 
N-terminal domain of a chemokine receptor and then to a different site on the chemokine 
receptor to induce activation. 
 
 
CXC chemokine receptor 4 (CXCR4) 
CXC chemokine receptor 4 (CXCR4) was initially discovered as an orphan receptor 
leukocyte-derived seven-transmembrane domain protein (LESTR) (84) and is encoded by the 
CXCR4 gene (25, 26). Recently, small protein antagonists were used to determine the crystal 
structure of CXCR4 and it provided additional evidence CXCR4 is capable of existing as a 
homo- and hetero-dimer on the cell surface (102). The currently known endogenous CXCR4 
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ligands are stromal-cell derived factor 1 (SDF-1!), macrophage migration inhibitory factor 
(MIF) and ubiquitin (28-32). Site-directed mutagenesis experiments suggest CXCR4 may 
have 2 separate ligand binding sites for ubiquitin and SDF-1! (44).  
 
CXCR4 ligands 
Stromal-cell derived factor-1 alpha (SDF-1!) 
 Human stromal cell-derived factor 1 alpha (SDF-1!), commonly referred to as 
chemokine (C-X-C motif) ligand (CXCL12), is a small (8 kDa) protein that is ubiquitously 
expressed in many tissues such as the liver, pancreas, and spleen (105). The CXCL12 gene 
encodes different isoforms of SDF-1, SDF-1! and SDF-1", and the two spice variants arise 
as a result of alternative splicing (103). SDF-1! exists as a monomer but can homo-dimerize 
under non-acidic pH conditions in the presence of stabilizing counterions and then displays 
partial agonist activity (104). While it has been well described that SDF-1! is the cognate 
ligand for CXCR4 and binds with high affinity (Kd: 1.5 – 24 nM) (106, 107), SDF-1! is 
promiscuous in that it has also been described as a CXCR7 agonist (33). Mutagenesis 
experiments to synthesize SDF-1! analogs and subsequent calcium flux and binding assays 
suggest SDF-1! utilizes the classical two-site binding mechanism of chemokine-receptor 
interactions (33-35, 36-39). The docking domain of SDF-1! interacts with the N-terminus of 
CXCR4 to bind to the receptor (site I) and the flexible N-terminus of SDF-1! interacts with 
the central binding pocket of CXCR4 (site II) to activate the receptor (40) (Figure 1-3). 
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Figure 1-3: Structural requirements of SDF-1!  for CXCR4 binding and activation: 
Depicted is a ribbon diagram of the structure of SDF-1!. The blue box in the middle of the 
image depicts the RFFESH residues on SDF-1! that interact with CXCR4 for docking. The 
blue box to the left depicts the K1 and P2 residues on SDF-1! that interact with CXCR4 for 
receptor activation. 
 
 
Ubiquitin 
 
Ubiquitin is a small (8.5 kDa), heat stable protein present in every eukaryotic cell (41) 
encoded by 4 mammalian genes. Recent mutagenesis experiments suggest UBA52 and 
RPS27A genes code for mono ubiquitin and UBB and UBC genes code for polyubiquitin 
precursor proteins (108). Ubiquitin is highly conserved and is most known for its intracellular 
functions in the ubiquitin-proteasome pathway of protein degradation (42). Ubiquitin is also 
present outside the cell and kinetic binding experiments suggest ubiquitin, like SDF-1!, 
binds to CXCR4 with a Kd of ~100 nM (28). Ubiquitin is distinct from SDF-1!, however, 
because it does not share CXCR7 as a receptor (43). Nuclear magnetic resonance (NMR) 
spectroscopy with the N-terminal domain of CXCR4, receptor binding and signaling studies 
in presence of antibodies directed against specific regions of CXCR4 suggesting ubiquitin, 
unlike SDF-1!, does not interact with the CXCR4 N-terminus for receptor docking (43). 
7 
 
Subsequent site-directed mutagenesis of CXCR4 followed by receptor binding experiments 
suggest there are distinct sites on the receptor important for ubiquitin-CXCR4 binding, but 
not for SDF-1! (43) (Figure 1-4).   
 
Figure 1-4: Molecular basis of the CXCR4 agonist activity of ubiquitin. Depicted is a 
ubiquitin-CXCR4 interaction model. Ubiquitin does not follow the typical two-site binding 
model of chemokine receptor interactions because the receptor N-terminus is not required for 
ubiquitin binding to CXCR4. 
 
Furthermore, experiments with ubiquitin point mutants suggest that the binding of ubiquitin 
to CXCR4 follows the two-site model of the structure function relationship of chemokines 
(44) (Figure 1-5). 
 
Figure 1-5: Structural requirements of ubiquitin for CXCR4 binding and activation: 
Depicted is a ribbon diagram of the structure of ubiquitin. The 2 blue boxes correspond to the 
blue arrows and show residues F4 and V70 interact with CXCR4 and are responsible for 
receptor docking. The red arrow corresponds to the red box on the model and shows G75 and 
G76 interact with CXCR4 for receptor activation. 
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Macrophage Migration Inhibitory factor (MIF) 
 
Macrophage migration inhibitory factor is a lymphokine that is encoded by the MIF 
gene and is a trimer comprised of three identical subunits (109, 110). It has been suggested 
MIF is a regulator of innate immunity by promoting pro-inflammatory functions of immune 
cells, specifically macrophage migration (111). While it has been described MIF is a ligand 
for CXCR4, MIF is promiscuous in that it has also been shown to bind CD74 and CXCR2 
(112). Information on the structure function relationship of the MIF-CXCR4 interaction is 
currently not available. 
 
CXCR4 signaling 
 CXCR4 signals through G-protein dependent and independent signaling upon ligand 
binding and signaling is regulated by three processes: receptor desensitization, receptor 
internalization, and receptor degradation (115). CXCR4 is a G!i coupled receptor and 
pertussis toxin, a potent G!i protein inhibitor, has been pivotal in elucidating the distinct 
signaling pathways (115). Through G-protein dependent signaling, it has been described 
CXCR4 can inhibit adenylyl cyclase, the enzyme that synthesizes cyclic adenosine 
monophosphate (cAMP) (115). Other resulting intracellular signals of G-protein mediated 
signaling are calcium fluxes and activation of focal adhesion components, protein kinase C 
(PKC), phospholipase C (PLC) as well as mitogen-activated protein kinases (MAPK p42/44) 
and phosphoinositide 3-kinase (PI3-K)/Protein Kinase B (PKB/Akt) activation (29, 50-52, 
53-59). 
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As previously described, G-protein independent signaling is thought to be mainly responsible 
for receptor desensitization. There is evidence, however, that the "-arrestin pathway also 
results in other signal transduction cascades, leading to cellular responses such as 
serine/threonine specific protein kinase activation (45, 61-63). 
 Serine/Threonine specific protein kinases are cell-signaling enzymes that 
phosphorylate the hydroxyl group of serine and threonine protein residues (64). These 
kinases can respond to extracellular stimuli and ultimately regulate a variety of cellular 
functions (64). There are many sub-classifications of these kinase types including mitogen-
activated protein kinase (MAPK) and protein kinase B (Akt). 
Mitogen-activated protein kinases (MAPKs) are signaling molecules involved in 
migration and survival. Activation of CXCR4 leads to G-protein mediated phosphorylation 
of the MAPK extracellular signal-related kinase (ERK) 1/2 (65-67) and subsequently ERK 
1/2 phosphorylates ribosomal S6 kinase (RSK) 1 (68) (Figure 1-6). It has also been described 
cell migration can be regulated by CXCR4 induced ERK1/2 activation (69,70). 
Protein kinase B (Akt) is a signaling molecule that is also involved in cell survival 
and migration (71,72). Akt has been implicated to be activated through CXCR4 mediated G-
protein signaling (66) (Figure 1-6). Akt also can regulate CXCR4 mediated cell migration 
(69,72). 
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Figure 1-6: G-protein coupled receptor mediated serine/threonine protein kinase 
activation: Left: G proteins function as guanine nucleotide exchange factors and act on Ras. 
Ras then binds Raf and initiates a phosphorylation cascade, acting on mitogen-activated 
protein kinase kinase MEK-1/2 and then activating ERK-1/2. Right: G proteins fucntion as 
guanine nucleotide exchange factors and act on PI3-K. PI3-K then phosphorylates the 3-OH 
position of phosphatidylinositol (4,5)-bisphosphate (PIP2) resulting in phosphatidylinositol 
(3,4,5)-trisphosphate PIP3. PIP3 then acts as a lipid anchor for phosphoinositide-dependent 
kinase-1 (PDK1) and Akt. Akt is then phosphorylated by PDK1 and PDK2. 
 
Function of CXC chemokine receptor 4 
CXCR4 is abundant in leukocytes and in most human tissues and plays pleiotropic 
roles as an immune modulator (27). CXCR4 is involved in platelet aggregation and reduces 
the production of tumor necrosis factor-! (TNF-!) and enhances interleukin (IL) 10 
production under inflammatory conditions (93-95). CXCR4 is crucial for normal 
development and CXCL12 (SDF-1!) and CXCR4 gene knockouts in mice models are 
embryonic lethal because the mice display defective vasculogenesis, neurogenesis, 
hematopoeisis, and cardiogenesis (73-77, 89, 90). It has also been described ubiquitin gene 
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knockouts are embryonic lethal but it is unknown if this is due to lack of ubiquitin-CXCR4 
binding (108). There are many disease states associated with CXCR4 dysregulation: 
When CXCR4 is in an unbound state, the receptor acts as a co receptor for human 
immunodeficiency virus (HIV-1) and has been described as a drug target for HIV-1 infection 
(78,79). The interaction between SDF-1! and CXCR4 has been shown to interfere with 
productive cellular entry of HIV-1 (34,35,80). This phenomenon does not occur when 
ubiquitin interacts with CXCR4 (43).  
CXCR4 is highly expressed on 23 different cancer cell types (115) including prostate, 
gastric, lung, and breast (85-88). CXCR4 has previously been implicated as a drug target for 
cancer (73,78) given that the regulation of chemotaxis is regarded as a key function of the 
CXCR4 signaling axis. Chemotaxis is the directed movement of cells toward a chemical 
gradient that is dependent on cell type and environmental conditions (81). As a result, 
CXCR4 expression may correlate with metastases, which is the spread of cancer from one 
part of the body to another (115). Gene expression profiles and in vivo studies suggest there 
are multiple cancer cell types that metastasize to areas that express high levels of SDF-1! 
(116,117). While variation exists between cancer cell types, CXCR4 mediated chemotaxis is 
regulated by a set of intracellular signal transduction pathways including G!i, PLC, 
PI3K/Akt and MAPK Erk1/2 activation (69,70,72,82,83).  
Warts, hypogammaglobulinemia, infection, and myelokathexis (WHIM) syndrome is 
a dominant inherited primary immunodeficiency disorder of the CXCR4 gene (96). Further 
genetic evidence suggests a single amino acid substitution in the carboxy-terminus of 
CXCR4 can lead to truncation of the C-terminal tail and elimination of possible 
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phosphorylation sites. The C-terminal tail truncation may lead to a hyperactive receptor, 
because GRKs can not phosohorylate the receptor and induce desensitization. This ultimately 
results in an increased responsiveness to SDF-1! (97,99). The lack of receptor 
desensitization (113) results in enhanced cellular chemotaxis (113), enhanced calcium flux 
(114), and a decrease in SDF-1! promoted internalization (113,114). The name of the 
disease describes the significant clinical symptoms (98). 
 
Rationale of study 
Biased agonists result in biased intracellular signaling and different biological functions 
through the same receptor, but the mechanisms leading to these effects are largely unknown. 
It is known that ubiquitin and SDF-1! bind to CXCR4 at distinct ligand binding sites (43). 
They do not, however, share CXCR7 as a receptor and ubiquitin also does not interfere with 
HIV-1 entry (43). We therefore propose that distinct ligand binding sites for ubiquitin and 
SDF-1! on CXCR4 are a structural correlate for biased agonism and result in different 
biological responses. The cellular consequences of ubiquitin induced CXCR4 activation, 
however, are still poorly defined and a side-by-side comparison of CXCR4 mediated 
functions after activation with SDF-1! and ubiquitin is lacking. This information will be 
instrumental to better understand the physiological roles of CXCR4 and to further define its 
role as a therapeutic target in various disease processes.
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CHAPTER TWO 
HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
Based on the foregoing literature review, we proposed the hypothesis that distinct 
ligand binding sites for ubiquitin and SDF-1!  on CXCR4 are a structural correlate for 
biased agonism and result in differential biological responses upon activation of 
CXCR4 with ubiquitin and SDF-1! . 
To address this hypothesis, we developed the following specific aims: 
Aim 1. To assess and compare the activation of important intracellular signal 
transduction pathways upon CXCR4 activation with SDF-1!  and ubiquitin. 
Aim 1A. To screen the phosphorylation status of multiple MAPKs after CXCR4 
activation with ubiquitin and SDF-1! utilizing a human phospho-MAPK array 
 Aim 1B. To confirm positive signals from the MAPK array by Western blotting 
 Aim 1 C. To define and compare the time course of phosphorylation of the
 identified MAPKs after CXCR4 activation with SDF-1! and ubiquitin 
Aim 2. To determine and compare the effects of ubiquitin and SDF-1!  on chemotaxis 
Aim 2A. To establish and optimize a chemotaxis assay 
 Aim 2B. To determine and compare chemotactic effects of ubiquitin and SDF-1! 
Aim 2C. To evaluate the signaling events leading to chemotaxis induced by  
ubiquitin and SDF-1!.
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CHAPTER THREE 
MATERIALS AND METHODS 
Materials:   
Ubiquitin: Ubiquitin was purchased from Boston Biochem (Cat # U-100) and 
suspended in 10 mM phosphate-buffered saline solution (PBS, containing 138 mM NaCl, 2.7 
mM KCl, 2 mM KH2PO4, and 10 mM Na2HPO4, pH 7.4, Sigma-Aldrich (Cat # P3813)). The 
working concentration varied by experiment. 
 N-Terminal Biotin labeled ubiquitin: N-terminal biotin labeled ubiquitin was 
purchased from Boston Biochem (Cat # UB-560) and suspended in PBS. 
 SDF-1!: SDF-1! was purchased from Peprotech (Cat # 300-28A) and was 
suspended in PBS. The working concentration varied by experiment. 
 Fetal Bovine Serum (FBS): FBS was purchased from Sigma-Aldrich (Cat # F6765). 
 Bovine Serum Albumin (BSA): BSA was purchased from Sigma-Aldrich (Cat # 
9048-46-8). 
Histopaque density gradient cell separation media (Histopaque): Histopaque was 
purchased from Sigma-Aldrich (Cat # 10771). 
Trypan blue: Trypan blue was purchased from Lonza (Cat # 17-942E) 
ELISA plate strips: ELISA plate strips were purchased from Greiner Bio-One (Cat # 
762061).
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3,3’,5’5, Tetramethylbenzidine (TMB): TMB was purchased from Sigma-Aldrich 
(Cat # T0440). 
 Super Signal West Dura Extended Duration Substrate (Substrate detection 
solution): Substrate detection solution was purchased from Thermo Scientific (Cat # 34075). 
Radioimmunoprecipitation assay (RIPA) Lysis and Extraction Buffer (RIPA 
buffer): RIPA buffer was purchased from Thermo Scientific (Cat # 89900). 
Sodium orthovanadate (Vanadate): Vanadate was purchased from New England 
BioLabs (Cat # P0758L) and suspended in double distilled water (ddH20) to a stock 
concentration of 100 mM. The working concentration used was 1 mM. 
Phenylmethylsulfonyl Fluoride (PMSF): PMSF was purchased from Santa Cruz 
Biotechnologies (Cat # SC-3597) and suspended in methanol to a stock concentration of 10 
mM. The working concentration used was 500 µM. 
Precision Plus Protein Dual Color standard (Protein standard): Protein standards 
were purchased from Bio Rad (Cat # 161-0374). 
Laemmli sample buffer: Laemmli sample buffer was purchased from Bio Rad (Cat # 
161-0737). 
Polyvinylidene fluoride (PVDF) Membranes (PVDF membranes): PVDF 
membranes were purchased from Bio Rad (Cat # 162-0174). 
Accustain Wright-Giemsa stain: Wright-Giemsa stain was purchased from Sigma-
Aldrich (Cat # WG128). 
Pertussis Toxin (catalyzes the ADP-ribosylation of !  subunit of heterotrimeric 
guanine nucleotide regulatory proteins; G! i proteins remain in GDP-bound “inactive” 
state): Pertussis Toxin (from Bordetella Pertussis) was purchased from Sigma-Aldrich (Cat 
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# P7208) and suspended in 500 µL ddH20 to a stock concentration of 0.1 mg/ml. The 
working concentration used for cell treatments was 100 ng/mL and the incubation time was 2 
hours, followed by a wash with PBS before experimentation. 
 U73312 (Inhibits the coupling of G protein-PLC activation, remaining 
unaffected by production of cAMP): U73312 was purchased from Sigma-Aldrich (Cat # 
U6756) and was suspended in dimethyl sulfoxide (DMSO) from Sigma-Aldrich, (Cat # 67-
68-5) to a stock concentration of 10 mM. The working concentration used for cell treatments 
was 5 µM, 0.1% DMSO and the incubation time was 30 minutes, followed by a wash with 
PBS before experimentation. 
U73343 (Inactive analog of U73312; used as a negative control): U73343 was 
purchased from Sigma-Aldrich, (Cat # U6881) and was suspended in DMSO to a stock 
concentration of 10 mM. The working concentration used for cell treatment was 5 µM, 0.1% 
DMSO and the incubation time was 30 minutes, followed by a wash with PBS before 
experimentation. 
 U0126 (Selectively binds to and inhibits MEK 1/2 activity thereby preventing 
ERK 1/2 phoshorylation and kinase activity): U0126 was purchased from Cell Signaling 
(Cat # 9903) and suspended in DMSO to a stock concentration of 10 mM.  The working 
concentration used for the cell treatment was 10 !M, 0.1% DMSO and the incubation time 
was 30 minutes, followed by a wash with PBS before experimentation. 
LY294002 (Selectively binds to and inhibits PI3 Kinase thereby preventing Akt 
phosphorylation and kinase activity): LY294002 was purchased from Cell Signaling (Cat 
# 9901S) and was suspended in DMSO to a stock concentration of 10 mM. The working 
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concentration used for cell treatments was 50 µM, 0.1% DMSO and the incubation time was 
1 hour, followed by a wash with PBS before experimentation. 
AMD3100 (Highly selective CXCR4 antagonist): AMD3100 was purchased from 
Sigma-Aldrich (Cat # A5602) and suspended in PBS to a stock concentration of 50 mM. The 
working concentration used for all cell treatments was 10 µM, followed by a wash with PBS 
before experimentation. 
Trichostatin A [(TSA), Histone deacetylase inhibitor): TSA was purchased from 
Selleck Chem (Cat # S1045) and suspended in DMSO to a stock concentration of 1 mM. The 
working concentration used for cell treatments was 20 µM, 0.1% DMSO and the incubation 
time was 18 hours, followed by a wash with PBS before experimentation. 
 
Antibodies: 
The primary antibodies used for Western blots were anti-phospho p90 ribosomal S6 
kinase (RSK1) (Ser-380) rabbit IgG, anti-phospho-ERK1 (Thr-202/Tyr-204)/ERK2 (Thr-
185/Tyr-187) rabbit-IgG and anti-phospho-Akt pan (Ser-473) rabbit IgG (all from R&D 
Systems), each diluted 1:2000 in PBS-1% Casein blocker solution (BioRad). The secondary 
antibody used was anti-rabbit IgG horseradish peroxidase (HRP)-linked whole antibody 
(Amersham Biosciences) and was diluted 1:5000 in PBS-1% Casein blocker solution.  
To control for protein loading, 1:1000 anti- Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mouse (Applied Biosystems) was used. The secondary antibody 
used was anti-mouse IgG HRP-linked whole antibody (Amersham Biosciences) diluted 
1:5000 in PBS-1% Casein blocker solution. 
18 
 
 The antibodies used for the competitive ubiquitin enzyme-linked immunosorbent 
assay (ELISA) were anti-ubiquitin and anti-biotin peroxidase conjugate both purchased from 
Sigma-Aldrich (Cat # U5379 and Cat # A4541, respectively) diluted 1:500 and 1:1000 in 
PBS-1% Casein blocker solution, respectively.  
Cells: 
 THP-1: THP-1 cells are a human acute monocytic leukemia cell line obtained from 
American Type culture collection depository (ATCC) (Cat # TIB-202). Cells were cultured 
in Roswell Park Memorial Institute medium from Sigma-Aldrich (RPMI 1640), (Cat # 
R0883) supplemented with 10% FBS and 2% Penicillin and Streptomycin from Sigma-
Aldrich (Cat # P4333). Cells were grown in a 37°C sterile, 95% humidified incubator 
supplemented with 5% CO2. Cell were split into two parts and incubated in fresh media every 
2-3 days. 
Peripheral blood mononuclear cell (PBMC): PBMCs, from human peripheral 
venous blood, that were drawn from healthy human donors of both sexes were isolated 
according to an IRB approved protocol (118). 
 
Experimental Methods: 
PBMC isolation: Histopaque solution was allowed to equilibrate to room 
temperature. Three milliliters of the histopaque solution were pipetted into 15-ml centrifuge 
tubes. Then, 3 mL of freshly drawn blood were pipetted into each centrifuge tube with 3 mL 
histopaque, ensuring the blood rested on the top of the histopaque solution. The centrifuge 
tubes were then centrifuged at 1400 revolutions per minute (RPM) for 30 minutes. After 
centrifugation, the top layer of serum was aspirated as not to disturb the middle white layer 
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of PBMCs. The PBMCs were then aspirated and placed into separate centrifuge tubes and 
washed with 10 mL of PBS. The tubes were then spun at 1100 RPM for 10 minutes. After 
centrifugation, the PBS solution was aspirated as not to disrupt the cell pellet. The cells were 
then washed again with 5 mL PBS and combined into a larger 50 mL conical tube. The 50 
mL conical tube was spun at 1100 RPM for 10 minutes. The PBS was aspirated and the 
PBMCs were suspended in 1 mL PBS; cells were then counted on a hematocytometer and 
diluted as required. 
Trypan Blue Cell Viability assay: The trypan blue viability assay was performed 
according to manufacturer recommendations (Lonza). The culture samples were prepared at a 
ratio of 1 part 0.4% trypan blue stain: 1 part culture sample; samples were then incubated at 
room temperature for 15 minutes. The cells were then counted under a microscope at 10x 
magnification on a hematocytometer. Non-viable cells stained blue and viable cells remained 
unstained. The percentage of viable cells is approximated by dividing the total number of 
viable cells by the total number of cells and then by multiplying by 100. 
Indirect Competitive Ubiquitin ELISA: The indirect competitive ubiquitin ELISA 
was performed as previously described (119). High Binding ELISA plate strips were coated 
with anti-ubiquitin and incubated for 18 hours at 4°C. The plates were washed three times 
with 200 µL PBS per well and were incubated with blocking buffer (1% BSA-PBS) for 1 
hour. After washing three times, 60 µL of 2 µg/mL ubiquitin standard solution or 60 µL of 
samples were mixed with 60 µL of 0.2 ng/mL biotinylated ubiquitin and placed in the plates. 
Each sample was tested in eight dilutions. Dilutions for the standard curve and test samples 
were prepared in blocking buffer. After incubation for 2 hours, the plates were washed with 
200 µL PBS, 0.01% Tween-20 (PBST) per well. Then, 100 µL of anti-biotin peroxidase 
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conjugate was added to each well. After one-hour incubation, the plates were washed again 
with PBST and 100 µL of TMB was added to each well. The reaction was stopped after 15 
minutes with 100 µL of 2N hydrochloric acid (HCl) added to each well. Optical densities 
were measured using a micro plate Biotek Synergy2 plate reader (test filter, 450 nm; 
reference filter, 540 nm). The ubiquitin concentration in the test sample was calculated with 
the Gen5 software for Windows program, Version 1.05.11 (Bio-Tek Instruments, Inc.), from 
a four-parameter logistic fit using ubiquitin as the standard (0-2000 ng/mL). The correlation 
coefficients for each standard curve were 0.998-1.  
Protein Kinase Phosphorylation Array: Screening of the phosphorylation status of 
various protein kinases after ubiquitin and SDF-1! stimulation was performed in THP-1 cells 
according to manufacturer’s instructions using a human phospho mitogen activated protein 
kinase (MAPK) antibody array from R&D Systems. 107 THP-1 cells were stimulated with 1 
µM of ubiquitin or SDF-1! for 10 minutes at 37ºC. Unstimulated cells served as controls in 
parallel experiments. Cells were lysed in 1 mL of lysis buffer on ice for 30 minutes, 
centrifuged (1,400 x g for 5 minutes) and the supernatant (=lysate) collected. 250 uL of the 
cell lysate was incubated with a pre-wet array membrane for 15 hours at 4ºC. After three 
washing steps at room temperature, array membranes were incubated with the diluted 
antibody cocktail for 2 hours at room temperature, washed and incubated with strepavidin-
HRP solution for 30 minutes at room temperature. After washing of the array membranes, 
substrate detection solution (prepared at a ratio of 1 luminol/enhancer solution: 1 stable 
peroxide buffer) was added for 5 minutes. Images of array membranes were then captured 
with a Chemi-doc XRS Imager [Quantity One V4.5.2 software (Bio-Rad)] for appropriate 
exposure times. 
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Preparation of cell lysates: Cells were washed with ice-cold PBS and centrifuged at 
1400 RPM for 5 minutes. After centrifugation, the supernatant was aspirated and the cell 
pellet remained on ice. Cells were lysed in RIPA buffer supplemented with 1 mM vanadate 
and 500 !M PMSF. Lysates were vortexted immediately for 10 seconds and then placed on 
ice.  Samples were then sonicated with a sonic demembrator, model 100 from Fisher-
Scientific, 2 times for 20-second intervals on ice. Samples remained on ice for 15 minutes 
and were then centrifuged for an additional 15 minutes, at 14000 RPM, 4ºC. The sample 
supernatant was then collected and placed in a clean centrifuge tube. 
Protein Quantification: Protein concentration was determined using a modified 
Bradford Bio-Rad DC Protein Assay Kit II (Cat # 500-0112). A BSA standard curve was 
generated with concentrations ranging from 0 mg/ml to 1.42 mg/ml. 5 uL of each standard 
was pippetted in duplicate into a 12-well clear flat bottom ELISA strip. 5 ul of each cell 
extract was pippetted in duplicate into a 12-well clear flat bottom ELISA strip. Then, 25 µL 
of reagent A, an alkaline copper tartrate solution, and then 200 µL of reagent B, a dilute 
Folin Reagent, were added to each well containing a standard or sample. The plate was then 
incubated on a shaker for 15 minutes at room temperature. The micro plate was then placed 
into a micro plate Biotek Synergy2 plate reader and the absorbance was read at 750 nm. The 
BSA protein standard absorbance was then plotted against the BSA protein standard 
concentration and a standard curve was generated by linear regression analysis. Protein 
concentration of an unknown sample was then calculated from the standard linear regression 
curve. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE): SDS-
PAGE was carried out using the Mini-Format Vertical Electrophoresis system from Bio-Rad, 
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and mini-protean TGX precast gels (8.6 cm x 6.7 cm, 0.1cm thickness) of 4-20% 
polacrylamide. Then, 2-10 µg/mL of the protein samples were suspended in Laemmli sample 
buffer and then loaded into each lane of the mini-cast gel. A protein standard was loaded in a 
lane of the mini-cast gel for all SDS-PAGE experiments. The polyacrylamide gels were run 
at 150V in 1X Tris/Glycine/SDS running buffer from BioRad for 45 minutes or until bands 
reached the bottom of the gel.   
Western Blot: PVDF membranes were presoaked for 5 seconds in 100% MeOH, and 
were then washed and equilibrated in transfer buffer (Milli-Q water (Millipore-Q Water 
Purification System, Millipore), 25 mM Tris/HCl, 192 mM glycine, 20% MeOH, pH 7.4). 
Extra thick mini blot size papers from BioRad were simultaneously equilibrated in transfer 
buffer. A transfer “sandwich” was then assembled according to standard protocol: Blot size 
paper, PVDF membrane, gel, blot size paper. The semi-dry transfer with transfer buffer was 
run at 25V for 48 minutes at room temperature. The PVDF membranes were then briefly 
rinsed in milli-Q water, then PBST. The membranes were then blocked in PBS-1% Casein 
blocker solution for 60 minutes. After blocking, the membranes were incubated with the 
respective primary antibodies in PBS-1% Casein blocker solution overnight at 4ºC. The 
membranes were washed 6 times in PBST for 6 minutes and incubated with horseradish 
peroxidase (HRP)-linked secondary antibody diluted 1:5000 in PBS-1% Casein blocker 
solution for 1 hour at room temperature. The membranes were washed again, 6 times in 
PBST for 6 minutes per wash. After the final wash, the membranes were incubated with the 
substrate detection solution (prepared 1 part luminol/enhancer solution to 1 part stable 
peroxide buffer) for 5 minutes. Membranes were then captured with a Chemi-doc XRS 
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Imager (Quantity One V4.5.2 software, Bio-Rad) for 0-60 second exposure time. Band 
densities were quantified using the densitometry analysis tool on the Quantity One program. 
  Filter Migration Assay: Chemotaxis was assessed using the ChemoTx 96-well cell 
migration system, manufactured by Neuroprobe. Each well of the lower portion of the micro 
plate apparatus was filled with 29 uL of the respective test solutions. The micro plate was 
then covered with the ChemoTx® filter. The cells were washed once with PBS, centrifuged 
at 1200 RPM and then the cells were re suspended in PBS to a concentration of 0-200,000 
cells per 25 uL. Then 25 uL of the cell solution was placed on the filter pore for each 
respective well. The plate was then covered and allowed to incubate at 37ºC for 0-6 hours. 
The plate was removed and the top of the filter was rinsed with PBS. The filter was then 
removed from the micro plate and the filter was allowed to dry. Then, ice cold 100% 
methanol was used to rinse the lower portion of the filter plate for 20 seconds. The methanol 
was poured off and then the filter was allowed to dry. A 6 mL mixture of 1 part ddH2O: 1 
part Wright-Giemsa stain was then prepared. The stain mixture was added to the lower 
portion of the filter plate. The plate was incubated at room temperature for 10-15 minutes, 
shaking every 2 minutes. The stain was rinsed off and the entire plate was then submerged in 
cool water twice using fresh water each wash. The filter plate was then allowed to dry. Each 
well on the lower portion of the filter plate was counted under a microscope at 400x 
magnification (average cell count of 3 non-overlapping fields of vision). The chemotactic 
index (CI), the ratio of cells that transmigrated through the filter in the presence versus the 
absence (=PBS/control) of the test solutions, was then calculated. 
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Statistics: 
 Data are expressed as mean ± standard error of the mean (SEM) of n 
independent experiments that were performed on different days. Differences between assays 
were analyzed with repeated measures analysis of variance (ANOVA) with Dunnett's 
multiple comparison tests as appropriate, to control for multiple testing. A two- tailed p < 
0.05 was considered significant. Data were analyzed using the GraphPad-Prism 5 software.
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CHAPTER FOUR 
RESULTS 
Specific Aim 1: To assess and compare the activation of important intracellular signal 
transduction pathways upon CXCR4 activation with SDF-1!  and ubiquitin. 
To exclude that changes of the ubiquitin concentration in the THP-1 cell culture 
supernatant would interfere with subsequent experiments, we measured cell viability, total 
cell number, and the ubiquitin concentration in the culture supernatant when cells were 
cultured in the presence and absence of serum for 0-72 hours. Fig. 4-1 (left panel) shows that 
the cell viability remained above 95% and the cell number increased when cells were 
cultured in the presence of serum. The cell viability decreased and the total cell number 
remained constant when cells were cultured without serum (Fig. 4-1 right panel). 
 
 
Figure 4-1. Cell number and percent cell viability of THP-1 cells during culture. THP-1 
cells were cultured for various time points, Cell number (!) and percent viability (") (n=3). 
Left: Cell number and percent cell viability when cells are cultured in the presence of serum. 
Right: Cell number and percent cell viability when cells are cultured without serum.
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Fig. 4-2 shows that the ubiquitin concentration in RPMI media alone at the beginning 
of cell culture was 15±3.0 ng/mL and 40±1.28 ng/mL after supplementation with serum. 
There was not an observable change of the ubiquitin concentration in RPMI media during 
cell culture with or without serum. These results suggest that for the chosen culture 
conditions, changes in the ubiquitin concentration of the culture supernatant in the presence 
or absence of serum will not interfere with subsequent experiments. 
 
 
Figure 4-2. Ubiquitin concentrations in THP-1 cell culture supernatants supplemented 
with or without serum. THP-1 cells were cultured for various time points and ubiquitin 
concentrations in the supernatant were measured with an indirect competitive ubiquitin 
ELISA (n=3). Left: Ubiquitin concentration of culture supernatant when cells are cultured in 
the presence of serum. Right: Ubiquitin concentration of culture supernatant when cells are 
cultured in the absence of serum. 
 
 
Aim 1A. To screen the phosphorylation status of multiple MAPKs after CXCR4 
activation with ubiquitin and SDF-1!  utilizing a human phospho-MAPK array 
To screen the phosphorylation status of multiple protein kinases after stimulating 
cells with ubiquitin and SDF-1!, THP-1 cells were incubated with 0 or 1 µM of ubiquitin or 
SDF-1! for 10 minutes at 37°C. Whole cell lysates were then probed for protein kinase 
phosphorylation utilizing a human phospho MAPK array. Fig. 4-3 shows representative 
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images of the array membranes from experiments when cells were treated with vehicle 
(control), ubiquitin, or SDF-1!. The numbers on the array membrane correspond to the spot 
positions for phosphorylated ERK1 (1), ERK2 (2), RSK 1 (3), Akt 1 (4), Akt 2 (5) and Akt 
pan (6). The chemiluminescence signal of each spot corresponds to the degree of 
phosphorylation of each protein kinase. Although there was considerable variation among the 
individual experiments for some of the protein kinases, cells stimulated with ubiquitin and/or 
SDF-1! consistently showed an increase in the densities of the spots that correspond to 
phosphorylated ERK1/2, RSK1, and Akt, as compared with untreated cells.  
 
Figure 4-3. Protein kinase phosphorylation after stimulation of THP-1 cells with 
ubiquitin and SDF-1! . A human phospho MAPK array was used to screen the 
phosphorylation status of multiple MAPKs. Typical images of the proteome array 
membranes after vehicle (control), ubiquitin, and SDF-1! treatment. The numbers on the 
array membrane correspond to the spot positions for phosphorylated ERK1 (1), ERK2 (2), 
RSK 1 (3), Akt 1 (4), Akt 2 (5) and Akt pan (6). 
 
 
 
 
28 
 
Fig. 4-4 shows the densitometric quantification of the spot densities that correspond to each 
phosphorylated protein kinase after treatment of THP-1 cells with ubiquitin and SDF-1! 
from 4 independent experiments; the spot densities are given as normalized pixel densities 
(1=control, dashed line). The floating bars (white: SDF-1! treatment; grey: ubiquitin 
treatment) extend from the minimum to the maximum and the horizontal line shows the 
mean. The chemiluminescence signals that correspond to ERK1/2, RSK1, and Akt, suggest 
that stimulation of THP-1 cells with ubiquitin and SDF-1! result in phosphorylation of the 
MAPKs, as compared to the unstimulated cells. 
 
 
Figure 4-4. Protein kinase phosphorylation after stimulation of THP-1 cells with 
ubiquitin and SDF-1! . A human phospho MAPK array was used to screen the 
phosphorylation status of multiple MAPKs. Densitometric quantification of spot densities, as 
in Fig. 4-3 (n=4). Spot densities are given as normalized pixel densities (1= unstimulated 
cells, dashed line). The bars (white: SDF-1! treatment; grey: ubiquitin treatment) extend 
from the minimum to the maximum; the horizontal line shows the mean.  
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Aim 1B. To confirm positive signals from the MAPK array by Western blotting 
To confirm the results from the proteome array that ERK1/2, Akt, and RSK1 are 
phosphorylated after THP-1 cells are stimulated with ubiquitin and SDF-1!, we treated THP-
1 cells with 1 µM ubiquitin or SDF-1! for 10 minutes and performed Western blot 
experiments. Fig. 4-5 shows representative images from Western blots performed with 
antibodies directed against phosphoERK1/2, phosphoAkt, and phosphoRSK1. The bands 
correspond to a phosphorylated serine/threonine protein kinase. Upon stimulation with 
ubiquitin or SDF-1!, there was an increase in the band density of phosphoERK1/2, 
phosphoAkt, and phosphoRSK1 as compared to cells that were not treated. Pretreatment of 
the THP-1 cells with the selective CXCR4 antagonist AMD3100 prevented the observed 
increase of the band densities that correspond to phosphoERK1/2, phosphoAkt, and 
phosphoRSK1 after cell stimulation with ubiquitin and SDF-1!. These results confirm that 
ERK1/2, Akt, and RSK1 are phosphorylated after THP-1 cells are stimulated with ubiquitin 
or SDF-1! and suggest that these effects are mediated through CXCR4. 
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Figure 4-5. CXCR4 induced protein kinase phosphorylation. Western blot analyses of 
MAPK phosphorylation after stimulation of THP-1 cells with ubiquitin and SDF-1!. Top 
(phosphoERK 1/2), Center (phosphoRSK1), Bottom (phosphoAkt). Cells were pre-treated 
with or without AMD3100 and stimulated with 1 µM of ubiquitin or SDF-1! for 10 minutes 
at 37°C, as indicated. 
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Aim 1C. To define and compare the time course of phosphorylation of the identified 
serine/threonine protein kinases after CXCR4 activation with SDF-1!  and ubiquitin 
 To define the time course of the respective serine/threonine protein kinase 
phosphorylation, we stimulated THP-1 cells with 1µM of ubiquitin or SDF-1! for 0, 5, 10, 
15, or 30 minutes and performed Western blot experiments with antibodies directed against 
phosphoERK1/2, phosphoAkt, and phosphoRSK1. The left panels of Fig. 4-6 show 
representative images from the Western blots. Upon stimulation with ubiquitin or SDF-1!, 
there were time dependent increases in the band densities corresponding to phospoERK1/2, 
phosphoAkt, and phosphoRSK1, as compared to untreated control. The right panels of Fig. 
4-6 show the densitometric quantifications of chemiluminescence signals of the bands after 
cell stimulation with ubiquitin or SDF-1! from 5-10 independent experiments. 
Measurements of the time progression of the phosphorylation status of these protein kinases 
confirm that cell activation with both ligands result in a comparable increase in protein 
kinase phosphorylation. With ubiquitin activation, the increase of phosphorylation occurred 
transiently and declined within 30 minutes. In contrast, the increase of phosphorylation was 
sustained for 30 minutes with SDF-1! activation. 
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Figure 4-6. Time course of CXCR4 induced protein kinase phosphorylation. Western 
blot analyses of MAPK phosphorylation after stimulation of THP-1 cells with ubiquitin and 
SDF-1!. Left panel: Top (pERK1/2), Center (pRSK1), Bottom (pAkt), after stimulation of 
cells with 1 µM of ubiquitin or SDF-1! for 0-30 minutes. Right panel: Quantification of the 
chemiluminescence signals after stimulation as on the left. White Bars: SDF-1! stimulation. 
Grey Bars: Ubiquitin stimulation. N=5-10. *: p<0.05 vs. unstimulated cells. 
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Specific Aim 2: To determine and compare the effects of ubiquitin and SDF-1!  on 
chemotaxis. 
Aim 2A. To establish and optimize a chemotaxis assay  
The regulation of cell trafficking is considered as a key function of the SDF-
1!/CXCR4 axis. Whether ubiquitin also has chemotactic activity, however, is unknown. 
Therefore, we used the chemotactic response of THP-1 cells as a functional read-out for 
CXCR4 agonist activity of ubiquitin and SDF-1!. Fig. 4-7 shows the average chemotactic 
indices (CI) from 7 independent filter migration experiments in which the concentration 
dependency of the chemotactic activity of ubiquitin and SDF-1! were tested. When 
compared with SDF-1!, cell migration towards ubiquitin was detectable at similar 
concentrations. However, the CI at concentrations that induced maximal cell migration was 
lower with ubiquitin (CI: 4.2±0.9 with ubiquitin vs. 7.1±1.4 with SDF-1!; p<0.05) (Fig. 4-7).  
 
 
Figure 4-7. SDF-1!/Ubiquitin induced chemotaxis. Dose dependent migration of THP-1 
cells toward a ubiquitin (#) and SDF-1! (!) gradient (n=7). *: p<0.05 vs. cells in the 
presence of PBS in lower compartment. 
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To provide additional evidence for chemotactic activity, we used ubiquitin, SDF-1!, 
and/or AMD3100 to disrupt the concentration gradients. Fig. 4-8 shows the migration of 
THP-1 cells in the presence or absence of ubiquitin, SDF-1! or AMD3100 (AMD, 10 µM) in 
the upper (top) and lower (bottom) compartment as indicated in the graph (n=4). Ubiquitin 
and SDF-1! were used at concentrations (2 experiments with 1 nM, 2 experiments with 10 
nM) that showed maximal chemotactic activity, as determined in Fig. 4-7. Induction of cell 
migration by ubiquitin and SDF-1! required a concentration gradient; AMD3100 also 
prevented cell migration. A SDF-1! concentration gradient induced a chemotactic response 
in the presence of ubiquitin, whereas ubiquitin concentration gradients did not produce 
chemotactic movements in the presence of SDF- 1!. This is consistent with the weaker 
chemotactic activity of ubiquitin that we determined in the dose response experiments from 
Fig. 4-7. These results suggest that both molecules possess chemotactic activity, which is 
mediated through CXCR4. 
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Figure 4-8. CXCR4 mediated chemotaxis.  Migration of THP-1 cells in the presence or 
absence of ubiquitin, SDF-1! or AMD3100 (AMD, 10 µM) in the upper (top) and lower 
(bottom) compartment, as indicated in the graph (n=4). Ubiquitin and SDF-1! were used at 
concentrations (2 experiments with 1 nM, 2 experiments with 10 nM) that showed maximal 
chemotactic activity, as determined in Fig. 4-7. *: p<0.05 vs. cells in the upper compartment 
and of ubiquitin in the lower compartment. #: p<0.05 vs. cells in the presence of PBS in the 
upper compartment and of ubiquitin in the lower compartment. ‡: p<0.05 vs. cells in the 
presence of PBS in the upper compartment and of SDF-1! in the lower compartment. 
 
 
There was considerable variability among the previous chemotaxis assays. Therefore, 
we sought to optimize the assay. To determine if the 8-micron filter pore size is appropriate 
for filter migration assays with THP-1 cells, we performed experiments in parallel with filter 
plates with an 8 or 5-micron pore size, respectively. Fig. 4-9 shows the average CIs from 3 
filter migration experiments performed in parallel on plates with 8-micron and with 5-micron 
pore sizes. Many of the CIs were higher on the 8-micron pore size plate compared to the 5-
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micron pore size plate. Therefore, this suggests that filter plates with 5-micron pore size limit 
chemotactic movement of THP-1 cells. Thus, plates with 8-micron pore size were used in 
subsequent experiments. 
 
Figure 4-9. Filter migration assay-filter plate pore size optimization. CIs from parallel 
filter migration assays performed with THP-1 cells on a 5 µm and 8 µm pore size plates 
(n=3). Cell migration of THP-1 cells we assessed toward a ubiquitin gradient (0.001-1000 
nM). 
 
 
We next evaluated the amount of time the THP-1 cells were allowed to incubate at 
37°C and performed filter migration assays at various incubation times. Fig. 4-10 shows the 
average CIs from 3 independent experiments when cells were incubated for 0, 2, 3, 4, or 6 
hours. The highest CI for ubiquitin, top, and SDF-1!, bottom, was observed after three 
hours. CI decreased when cells were allowed to incubate for more than 3 hours and decreased 
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near control CI values by 6 hours. This suggests that the optimal time to incubate the cells for 
filter migration assays is 3 hours. 
 
 
 
Figure 4-10. Filter migration assay-cell incubation time optimization. Filter migration 
assays were performed with THP-1 cells and were allowed to incubate for 0-6 hours (n=3). 
Top: Ubiquitin and Bottom: SDF-1!, were used at a concentration (10 nM) that showed 
maximal chemotactic activity, as determined in Fig. 4-7.  
 
 
Lastly, we optimized the cell number used for each well on the chemotaxis filter 
plate. Fig. 4-11 shows the average CIs from 6 independent filter migration experiments using 
an 8-micron pore size plate and 3 hour incubation time at 37°C with either 5 x 104, 10 x 104, 
or 20 x 104 cells per well. Ubiquitin and SDF-1! were used at a concentration (10 nM) that 
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showed maximal chemotactic activity, as determined in Fig. 4-7. The highest CI for ubiquitin 
and SDF-1! was observed using 20 x 104 cells per well. 
    
Figure 4-11. Filter migration assay-cell number optimization. Cell migration assays using 
5 x 104, 10 x 104, and 20 x 104 THP-1 cells per well towards (Left): ubiquitin and (Right): 
SDF-1! (n=6). Ubiquitin and SDF-1! were used at a concentration (10 nM) that showed 
maximal chemotactic activity, as determined in Fig. 4-7. 
 
 
Aim 2B. To determine and compare chemotactic effects of ubiquitin and SDF-1!  under 
optimized conditions 
 To compare the chemotactic effects of ubiquitin and SDF-1!, we repeated the filter 
migration experiments under optimized conditions. Fig. 4-12 shows the average CIs from 6 
independent cell migration experiments. THP-1 cells migrated dose dependently towards 
ubiquitin and SDF-1!, as was described before (Fig. 4-7). Under optimized conditions, 
ubiquitin is 4-5 times less efficacious than SDF-1! in promoting chemotaxis because the CI 
at concentrations that induced maximal cell migration was lower with ubiquitin (CI: 5.99±1.1 
with ubiquitin vs. 19.89±3.28 with SDF-1!). SDF-1! and ubiquitin are of similarly potency 
because the concentrations that induced cell migration are similar for both ligands. 
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Figure 4-12. Filter migration assays performed under optimized conditions. Filter 
migration assays using 20 x 104 THP-1 cells toward a ubiquitin (!) and SDF-1! (!) 
gradient (n=6). 
 
It is known that SDF-1! directs migration of freshly isolated leukocytes, but it is 
unknown whether ubiquitin also induces migration. Therefore, to assess whether ubiquitin 
also directs cell migration of leukocytes, we isolated PBMCs from human venous blood and 
performed filter migration assays. We first performed experiments with 8 and 5-micron pore 
size filter plates, respectively, to assess whether the 8-micron filter pore size is appropriate 
for PBMCs. Fig. 4-13 shows the average CIs from 3 chemotaxis experiments performed in 
parallel on plates with a 5-micron pore size and on plates with 8-micron pore size. The 
correlation of the CIs from experiments done in parallel on plates with a 5 and 8-micron filter 
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pore size is linear. Therefore, either the 8 or 5-micron filter pore size plates are suitable and 
we used 8-micron filter pore size plates for experiments with PBMCs. 
  
 
Figure 4-13. Filter plate pore size optimization of migration assays with freshly isolated 
leukocytes. CIs from experiments using PBMCs performed in parallel on plates with 5 and 
8-micron pore size (n=3). Cell migration of PBMCs toward a ubiquitin gradient (0.001-1000 
nM) (r2=0.1499). 
 
Fig. 4-14 shows the average CIs from 5 independent filter migration experiments 
using an 8-micron filter pore size plate under conditions described for THP-1 cells. PBMCs 
migrated dose dependently towards ubiquitin and SDF-1!. Compared with SDF-1!, cell 
migration towards ubiquitin was detectable at similar concentrations. However, the CI at 
concentrations that induced maximal cell migration was lower with ubiquitin (5±0.48) 
compared to SDF-1!  (27±3.3). Similar to THP-1 cells (Fig. 4-12), ubiquitin is 4-5 times less 
efficacious than SDF-1! in promoting chemotaxis, but of similar potency. 
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Figure 4-14. Filter migration assays with PBMCs. Dose dependent migration of PBMCs 
toward a ubiquitin (#) and SDF-1! (!) gradient (0.001-1000 nM) (n=5).  
 
 
Aim 2C. To characterize the signaling events leading to chemotaxis induced by 
ubiquitin and SDF-1!  
 
 The intracellular signals responsible for chemotaxis in response to SDF-1! have been 
previously characterized (69,70,72,82,83); whether these signals are responsible for 
chemotaxis in response to ubiquitin is unknown. Therefore, to characterize the intracellular 
signals that are responsible for chemotaxis after cells are stimulated with ubiquitin, we 
disrupted cognate CXCR4 signaling pathways with a variety of well-described 
pharmacological agents. Fig. 4-15 shows the CIs of THP-1 cells that were incubated with a 
pharmacological inhibitor, as compared to untreated control cells, from eight independent 
experiments. The bars on the graphs (left: ubiquitin treatment; right: SDF-1! treatment) 
correspond to the pharmacological agent used to disrupt the intracellular signals responsible 
for chemotaxis. AMD3100, Pertussis Toxin, U73122, U73343 LY294002 and U0126 
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significantly decreased chemotaxis of THP-1 cells for both ubiquitin and SDF-1!, as 
compared to control. Further, TSA (used as a non-specific control) did not significantly 
decrease the CIs of THP-1 cells for both ligands. 
   
Figure 4-15. Intracellular signals responsible for CXCR4 mediated chemotaxis, THP-1 
cells. Pharmacological agents as previously described were used to treat THP-1 cells and 
characterize the signaling pathways responsible for chemotaxis after ubiquitin and SDF-1! 
stimulation. The amount of chemotaxis compared to untreated cells (white) was measured. 
Ubiquitin (Left) and SDF-1! (Right) were used at a concentration (10 nM) that showed 
maximal chemotactic activity, as determined in Fig. 4-7 (n=8) *: p<0.05 vs. untreated control 
cells.  
 
 
Next, we evaluated the effects of the pharmacological inhibitors on freshly isolated 
leukocytes to assess whether the intracellular signals that are responsible for cell migration in 
THP-1 cells are similar for PBMCs. Fig. 4-16 shows the CIs of PBMCs that were incubated 
with a pharmacological inhibitor compared to untreated control cells from six independent 
experiments. The bars on each graph (left: ubiquitin treatment; right: SDF-1! treatment) 
correspond to the pharmacological agent used to disrupt the intracellular signals responsible 
for chemotaxis in PBMCs. Similar to Fig. 4-15, AMD3100, Pertussis Toxin, U73122, 
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U73343, LY294002 and U0126 also significantly decreased the CIs of PBMCs for both 
ubiquitin and SDF-1!, as compared to control.  
   
Figure 4-16. Intracellular signals responsible for CXCR4 mediated chemotaxis, 
PBMCs. Pharmacological agents as previously described were used to treat PBMCs and 
characterize the signaling pathways responsible for chemotaxis after ubiquitin and SDF-1!. 
The amount of chemotaxis compared to untreated cells was measured. Ubiquitin (Left) and 
SDF-1! (Right) were used at a concentration (10 nM) that showed maximal chemotactic 
activity, as determined in Fig. 4-7. (n=6) *: p<0.05 vs. untreated control cells. 
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CHAPTER FIVE 
DISCUSSION 
Ubiquitin was recently characterized as a CXCR4 agonist but the intracellular 
responses after CXCR4 activation with ubiquitin are largely unknown. In this study, we 
investigated whether the distinct ligand binding sites for ubiquitin and SDF-1! on CXCR4 
resulted in differential biological responses. Our results suggest that activation of CXCR4 
with ubiquitin and SDF-1! result in similar intracellular signaling events and functional 
consequences. Ubiquitin appears to be a weaker CXCR4 agonist than SDF-1!, however, and 
this may correspond to differential CXCR4 signaling mediated via distinct ligand binding 
sites on the receptor. 
 Our initial result provided evidence that we maintained healthy cells under our culture 
conditions, and that the ubiquitin concentration in the culture supernatant would not interfere 
with experiments to test our hypothesis. Our first finding that CXCR4 activation with 
ubiquitin appears to result in similar intracellular signaling properties compared to SDF-1! is 
supported by the MAPK array and subsequent Western blot experiments. Side-by-side 
comparisons of MAPK phosphorylations after ubiquitin and SDF-1! stimulation of THP-1 
cells showed that both ligands produced similar patterns in the membrane array. We then 
used Western blot experiments and confirmed that ERK-1/2, RSK-1 and Akt are 
phosphorylated in response to CXCR4 activation after cell stimulation with ubiquitin and 
SDF-1! (53,120). Thus, the original thought was that the similar pattern of MAPK
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phosphorylation, after CXCR4 activation with both ligands, argues against differential 
intracellular signaling properties (121). However, the time course Western blot experiments 
provided evidence that there are differential signaling properties; MAPK phosphorylation 
after CXCR4 activation with ubiquitin occurred more transiently compared to SDF-1!. It 
might be speculated that the transient effects of MAPK phosphorlyation after cells were 
incubated with ubiquitin may be due to increased activity of phosphatases specific for 
ERK1/2, RSK-1, and Akt. However, it is unknown whether CXCR4 activation with ubiquitin 
or SDF-1! results in phosphatase over expression and/or activation. 
 Our finding that CXCR4 activation with ubiquitin appears to result in a similar 
functional response compared to SDF-1! is supported by our filter migration experiments. 
We used THP-1 cells and freshly isolated leukocytes and found that SDF-1! and ubiquitin 
displayed chemotactic activity at concentrations between 0.1 – 10 nM. This is in agreement 
with the wide range of SDF-1! concentrations that have been previously reported to induce 
chemotactic movements (130,131). Thus, it is reasonable to speculate that ubiquitin and 
SDF-1! induced maximal receptor activation at these optimized concentrations. These 
results also correspond to previous observations that intramuscular injection of ubiquitin led 
to the accumulation of large numbers of lymphocytes in the CXC12 myoblast cell line (132), 
which resembles the effects of SDF-1! after subcutaneous injection (122). Further, these 
findings are concurrent with the affinity of SDF-1! for CXCR4 (Kd: 1.5 – 24 nM), which 
has been reported with human peripheral blood monocytes, T-cells, and T-cell lines (32, 106, 
107,133, 134). However, the range of concentrations observed that induced chemotactic 
responses towards ubiquitin were 10-1000-fold below the affinity of ubiquitin for CXCR4 
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(28). We can speculate that the lower chemotactic response is not due to the lower affinity of 
ubiquitin for CXCR4, as compared to SDF-1!, because CXCR4 is fully activated with 
ubiquitin under optimized conditions. Thus, It is possible that this phenomenon is a result of 
the alternative ubiquitin-binding site on CXCR4 (43). These results suggest, however, that 
only a small percentage of receptor occupancy by ubiquitin is necessary to elicit a cellular 
response. Such a dose-response relationship has been described for other GPCRs, showing 
half-maximal and maximal responses at receptor occupancies of 0.13% and of 0.8% (135, 
136), respectively. We also optimized the filter migration assay (filter pore size, time cells 
were allowed to incubate, and cell number used per well) and confirmed and extended 
previously described results under optimized conditions (26, 122).  
 Our findings from filter migration experiments after we disrupted cognate CXCR4 
signaling pathways show that CXCR4 activation with ubiquitin and SDF-1! result in similar 
intracellular signaling properties. The finding that THP-1 cells and PBMCs migrated toward 
ubiquitin or SDF-1!, that both ligands function through CXCR4 (133,138), and cells rely on 
a similar pattern of intracellular signaling including G!i (32), PLC (138), PI3 kinase (139) 
and ERK1/2 (137,140) to induce chemotaxis is in agreement with previous literature. It must 
be noted that pre-treatment of cells with U73122 had the strongest effects in both cell types 
and this may explain why there was a significant reduction in chemotaxis when cells were 
pre-treated with U73343.  
Several studies show that CXCR4-"-arrestin signaling leads to phosphorylation of 
ERK1/2 and Akt, and may results in prolonged signal transduction events (123-125). There 
are also studies that show "-arrestin mediated signaling leads to prolonged ERK1/2 signaling 
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and actin filament assembly at the leading edge of cells that is critical for GPCR mediated 
chemotactic responses (126-129). Thus, the transient MAPK phosphorylation after cell 
stimulation with ubiquitin and the lower efficacy of ubiquitin to induce a chemotactic 
response in THP-1 cells and PBMCs could suggest there is insufficient "-arrestin recruitment 
to CXCR4 after ubiquitin stimulation. 
One limitation of our study is that our filter migration assays have thus far been 
conducted in vitro using THP-1 cells and PBMCs. There is evidence that multiple cancer cell 
types metastasize to SDF-1! (116, 117), and ubiquitin may have important therapeutic 
potential for cancer treatment. In order to confirm the results from our experiments, in vivo 
experiments are required. Another limitation is that, although Western blot experiments 
showed MAPK phosphorylation after cell stimulation with ubiquitin and SDF-1!, this was 
not indicative of the activity of the MAPKs and may not influence cellular function. 
Additionally, using PBMCs was a limitation for this study because PBMCs are not a 
homogenous cell population. The last limitation of note was while the pharmacological 
inhibitors used in the experiments have been well described, we would need to perform 
additional experiments to confirm that the intracellular signals are inactive. 
Working model for CXCR4 activation with ubiquitin and SDF-1!  
 The results from the current study show that ubiquitin induces serine/threonine 
protein kinase activation in THP-1 cells and this appears to be specific through CXCR4. 
However, the response was more transient compared to SDF-1! induced CXCR4 activation. 
Additionally, the results demonstrate ubiquitin induces a chemotactic response specific 
through CXCR4 with THP-1 cells and PBMCs, but the response was less compared to SDF-
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1!. However, the signaling events we tested that are involved in a chemotactic response were 
similar for ubiquitin and SDF-1!. In summary, the transient serine/threonine protein kinase 
activation and differences in chemotaxis may be explained by the amount of "-arrestin 
recruitment to the activated receptor. A working model is presented in Figure 5-1. 
Future directions for the investigation of functional selectivity through CXCR4 
activation with ubiquitin and SDF-1!  
 It has been described that "-arrestin is a crucial intracellular signal transducer and 
leads to functional responses. Therefore, a future study could investigate the magnitude of "-
arrestin recruitment to CXCR4 upon stimulation with ubiquitin and SDF-1!. Additionally, 
GRKs phosphorylate CXCR4 at the third intracellular loop and this results in the active 
recruitment and increased affinity of "-arrestin to the receptor. Therefore a study of the 
interaction of GRKs with CXCR4 after activation with ubiquitin and SDF-1!, the 
phosphorylation status of the third intracellular loop of CXCR4, and finally the magnitude of 
"-arrestin recruitment to CXCR4 would provide additional evidence of differential receptor 
signaling. 
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Figure 5-1. Working hypothesis for differential signaling through CXCR4 activation 
with ubiquitin and SDF-1! . Our data demonstrate that ubiquitin induces serine/threonine 
protein kinase activation in THP-1 cells and this is specific through CXCR4. Our data also 
showed ubiquitin induces a chemotactic response specific through CXCR4 mediated 
intracellular signals. The serine/threonine kinase signals were more transient and chemotaxis 
was less with ubiquitin compared to SDF-1!. It is possible ubiquitin is a biased agonist and 
there is minimal or even no "-arrestin signaling with ubiquitin induced CXCR4 activation. 
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